BCRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.80%

Insider Buying (Last 12 Months): $596,337.56

Insider Selling (Last 12 Months): $82,486.00

BioCryst Pharmaceuticals Insider Trading History Chart

BioCryst Pharmaceuticals Share Price & Price History

^$8.61

▲ +0.14 (1.65%)

As of 02/28/2025 05:00 PM ET

Days: 30 | 90 | 365

BioCryst Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2024	Amy E Mckee	Director	Sell	8,600	$6.32	$54,352.00	27,831
6/17/2024	Machelle Sanders	Director	Sell	4,689	$6.00	$28,134.00	27,742
5/30/2024	Alan G Levin	Director	Buy	7,861	$6.36	$49,995.96	44,951
5/24/2024	Steve Aselage	Director	Buy	2,500	$6.40	$16,000.00	2,500
5/20/2024	Nancy J. Hutson	Director	Buy	5,000	$6.38	$31,900.00	86,818
5/14/2024	Anthony Doyle	CFO	Buy	36,300	$5.57	$202,191.00	266,744
5/14/2024	Helen M Thackray	Insider	Buy	30,000	$5.86	$175,800.00	272,139
5/13/2024	Steven K Galson	Director	Buy	21,940	$5.49	$120,450.60	51,551
6/15/2023	Machelle Sanders	Director	Sell	4,000	$7.98	$31,920.00	25,611
2/1/2023	Jon P. Stonehouse	CEO	Sell	100,000	$10.38	$1,038,000.00	1,008,739
12/15/2022	Anthony Doyle	CFO	Sell	5,700	$10.90	$62,130.00	163,966
12/15/2022	Helen M Thackray	Insider	Sell	3,125	$10.89	$34,031.25	133,275
12/15/2022	Jon P. Stonehouse	CEO	Sell	14,100	$10.90	$153,690.00	887,730
12/15/2022	Michael L Jones	Director	Sell	445	$10.90	$4,850.50	10,753
12/2/2022	Jon P. Stonehouse	CEO	Sell	82,656	$12.80	$1,057,996.80	901,830
12/1/2022	Michael L Jones	Director	Sell	8,600	$13.01	$111,886.00	11,198
11/14/2022	Yarlagadda S. Babu	Insider	Sell	31,515	$13.88	$437,428.20	298,541
4/1/2022	Helen M Thackray	Insider	Sell	7,600	$16.20	$123,120.00	136,400

See Full Table

SEC Filings (Institutional Ownership Changes) for BioCryst Pharmaceuticals (NASDAQ:BCRX)

85.88% of BioCryst Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioCryst Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/27/2025	Pinnacle Wealth Planning Services Inc.	12,710	$96K	0.0%	-48.6%	0.006%
2/20/2025	Mackenzie Financial Corp	84,662	$0.64M	0.0%	+190.7%	0.041%
2/19/2025	GF Fund Management CO. LTD.	4,349	$33K	0.0%	N/A	0.002%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	401,111	$3.02M	0.0%	+3.0%	0.194%
2/17/2025	Voloridge Investment Management LLC	1,579,960	$11.88M	0.0%	-11.9%	0.763%
2/17/2025	Woodline Partners LP	450,199	$3.39M	0.0%	N/A	0.217%
2/17/2025	Visionary Wealth Advisors	26,590	$0.20M	0.0%	-4.3%	0.013%
2/17/2025	Two Sigma Advisers LP	2,499,812	$18.80M	0.0%	+14.6%	1.207%
2/17/2025	Two Sigma Investments LP	1,774,214	$13.34M	0.0%	+0.8%	0.857%
2/17/2025	Teza Capital Management LLC	47,874	$0.36M	0.1%	-9.2%	0.023%
2/17/2025	State of Wyoming	42,303	$0.32M	0.0%	-19.4%	0.020%
2/17/2025	Sherbrooke Park Advisers LLC	34,628	$0.26M	0.1%	+25.9%	0.017%
2/17/2025	Rafferty Asset Management LLC	234,836	$1.77M	0.0%	-36.7%	0.113%
2/17/2025	ProShare Advisors LLC	68,004	$0.51M	0.0%	+32.6%	0.033%
2/17/2025	Quantinno Capital Management LP	14,828	$0.11M	0.0%	+38.2%	0.007%
2/17/2025	Parkman Healthcare Partners LLC	216,881	$1.63M	0.2%	-53.3%	0.105%
2/17/2025	Man Group plc	89,954	$0.68M	0.0%	+46.3%	0.043%
2/17/2025	Nuveen Asset Management LLC	3,419,046	$25.71M	0.0%	-29.0%	1.651%
2/17/2025	Millennium Management LLC	790,105	$5.94M	0.0%	-44.5%	0.381%
2/17/2025	Lazard Asset Management LLC	161,516	$1.21M	0.0%	+68.1%	0.078%
2/17/2025	Jacobs Levy Equity Management Inc.	247,795	$1.86M	0.0%	-32.6%	0.120%
2/17/2025	Graham Capital Management L.P.	97,257	$0.73M	0.0%	N/A	0.047%
2/17/2025	D. E. Shaw & Co. Inc.	315,263	$2.37M	0.0%	+37.6%	0.152%
2/17/2025	Deutsche Bank AG	519,217	$3.91M	0.0%	+12.7%	0.251%
2/17/2025	Deerfield Management Company L.P. Series C	8,144,442	$61.25M	1.2%	+0.1%	3.932%
2/17/2025	Corton Capital Inc.	32,337	$0.24M	0.1%	-18.1%	0.016%
2/17/2025	Brevan Howard Capital Management LP	56,644	$0.43M	0.0%	-28.7%	0.027%
2/17/2025	Balyasny Asset Management L.P.	529,653	$3.98M	0.0%	N/A	0.256%
2/17/2025	Bayesian Capital Management LP	25,700	$0.19M	0.0%	N/A	0.012%
2/17/2025	Bank of America Corp DE	899,838	$6.77M	0.0%	-22.5%	0.434%
2/17/2025	BNP Paribas Financial Markets	196,225	$1.48M	0.0%	-60.5%	0.095%
2/17/2025	Ameriprise Financial Inc.	1,720,581	$12.94M	0.0%	-2.9%	0.831%
2/17/2025	Algert Global LLC	725,305	$5.45M	0.1%	+40.5%	0.350%
2/14/2025	Caligan Partners LP	2,995,932	$22.53M	6.0%	+16.0%	1.446%
2/14/2025	Freestone Grove Partners LP	30,313	$0.23M	0.0%	N/A	0.015%
2/14/2025	Schonfeld Strategic Advisors LLC	217,740	$1.64M	0.0%	+27.3%	0.105%
2/14/2025	AQR Capital Management LLC	839,274	$6.31M	0.0%	+6.6%	0.405%
2/14/2025	Northern Trust Corp	2,004,911	$15.08M	0.0%	+7.7%	0.968%
2/14/2025	The Manufacturers Life Insurance Company	103,531	$0.78M	0.0%	-65.4%	0.050%
2/14/2025	Tudor Investment Corp ET AL	99,450	$0.75M	0.0%	N/A	0.048%
2/14/2025	Aquatic Capital Management LLC	55,890	$0.42M	0.0%	-58.9%	0.027%
2/14/2025	Oxford Asset Management LLP	13,165	$99K	0.1%	N/A	0.006%
2/14/2025	Boothbay Fund Management LLC	1,384,633	$10.41M	0.3%	+16.0%	0.668%
2/14/2025	Susquehanna Fundamental Investments LLC	88,854	$0.67M	0.0%	N/A	0.043%
2/14/2025	Virtus ETF Advisers LLC	46,007	$0.35M	0.1%	-13.0%	0.022%
2/14/2025	Empire Financial Management Company LLC	35,000	$0.26M	0.1%	-40.7%	0.017%
2/14/2025	Voya Investment Management LLC	625,905	$4.71M	0.0%	-29.2%	0.302%
2/14/2025	Syon Capital LLC	13,149	$99K	0.0%	N/A	0.006%
2/14/2025	Price T Rowe Associates Inc. MD	126,806	$0.95M	0.0%	-94.4%	0.061%
2/14/2025	Dark Forest Capital Management LP	29,693	$0.22M	0.0%	-39.9%	0.014%
2/14/2025	Eversept Partners LP	1,980,312	$14.89M	1.3%	+269.9%	0.956%
2/14/2025	Hsbc Holdings PLC	90,061	$0.68M	0.0%	+33.9%	0.043%
2/14/2025	Rock Springs Capital Management LP	2,677,996	$20.14M	0.8%	-26.1%	1.293%
2/14/2025	Tower Research Capital LLC TRC	23,083	$0.17M	0.0%	+84.7%	0.011%
2/14/2025	MetLife Investment Management LLC	126,949	$0.96M	0.0%	+6.0%	0.061%
2/14/2025	First Trust Advisors LP	565,215	$4.25M	0.0%	-4.8%	0.273%
2/13/2025	Jump Financial LLC	263,338	$1.98M	0.0%	-3.1%	0.127%
2/13/2025	XTX Topco Ltd	21,069	$0.16M	0.0%	-33.5%	0.010%
2/13/2025	Mariner LLC	13,258	$100K	0.0%	+32.1%	0.006%
2/13/2025	Capital Fund Management S.A.	59,327	$0.45M	0.0%	-83.4%	0.029%
2/13/2025	Raymond James Financial Inc.	10,670	$80K	0.0%	N/A	0.005%
2/13/2025	Renaissance Technologies LLC	545,021	$4.10M	0.0%	-7.5%	0.263%
2/13/2025	Legal & General Group Plc	275,083	$2.07M	0.0%	+3.9%	0.133%
2/13/2025	Invesco Ltd.	1,072,600	$8.07M	0.0%	+6.7%	0.518%
2/13/2025	Cerity Partners LLC	11,992	$90K	0.0%	-51.4%	0.006%
2/13/2025	Federated Hermes Inc.	167,957	$1.26M	0.0%	+51.3%	0.081%
2/13/2025	Russell Investments Group Ltd.	27,966	$0.21M	0.0%	+86.1%	0.014%
2/13/2025	Wells Fargo & Company MN	104,163	$0.78M	0.0%	+53.2%	0.050%
2/12/2025	Arete Wealth Advisors LLC	20,200	$0.15M	0.0%	+67.6%	0.010%
2/12/2025	Cinctive Capital Management LP	194,386	$1.46M	0.1%	-29.0%	0.094%
2/12/2025	Knott David M Jr	440,000	$3.31M	1.2%	+15.2%	0.212%
2/12/2025	Trexquant Investment LP	494,356	$3.72M	0.0%	-43.9%	0.239%
2/12/2025	Geode Capital Management LLC	4,823,735	$36.28M	0.0%	-0.3%	2.329%
2/12/2025	Franklin Resources Inc.	262,382	$1.97M	0.0%	-0.5%	0.127%
2/12/2025	Wellington Management Group LLP	89,057	$0.67M	0.0%	-17.4%	0.043%
2/12/2025	Schroder Investment Management Group	522,657	$3.94M	0.0%	+523.9%	0.252%
2/12/2025	Arrowstreet Capital Limited Partnership	403,412	$3.03M	0.0%	-6.5%	0.195%
2/12/2025	Pictet Asset Management Holding SA	26,442	$0.20M	0.0%	+34.9%	0.013%
2/12/2025	Norges Bank	524,804	$3.95M	0.0%	N/A	0.253%
2/12/2025	JPMorgan Chase & Co.	474,376	$3.57M	0.0%	-17.8%	0.229%
2/11/2025	Segall Bryant & Hamill LLC	1,422,196	$10.70M	0.1%	-4.6%	0.687%
2/11/2025	Prudential Financial Inc.	983,033	$7.39M	0.0%	+10.2%	0.475%
2/11/2025	Corebridge Financial Inc.	102,731	$0.77M	0.0%	-7.0%	0.050%
2/11/2025	Vanguard Group Inc.	21,890,422	$164.62M	0.0%	+7.8%	10.568%
2/11/2025	LPL Financial LLC	13,932	$0.11M	0.0%	-12.2%	0.007%
2/11/2025	Fox Run Management L.L.C.	68,040	$0.51M	0.1%	+67.4%	0.033%
2/11/2025	KLP Kapitalforvaltning AS	39,800	$0.30M	0.0%	N/A	0.019%
2/11/2025	Hillsdale Investment Management Inc.	542,100	$4.08M	0.2%	+65,213.3%	0.262%
2/11/2025	Sei Investments Co.	57,190	$0.43M	0.0%	+2.8%	0.028%
2/11/2025	Semanteon Capital Management LP	197,760	$1.49M	0.8%	+32.2%	0.095%
2/11/2025	Teacher Retirement System of Texas	58,291	$0.44M	0.0%	+25.1%	0.028%
2/11/2025	Xponance Inc.	14,896	$0.11M	0.0%	+9.1%	0.007%
2/11/2025	Intech Investment Management LLC	97,793	$0.74M	0.0%	+80.3%	0.047%
2/10/2025	Cibc World Markets Corp	19,338	$0.15M	0.0%	N/A	0.009%
2/10/2025	May Barnhard Investments LLC	30,000	$0.23M	0.1%	N/A	0.014%
2/10/2025	Commonwealth Equity Services LLC	139,132	$1.05M	0.0%	-2.5%	0.067%
2/10/2025	Swiss National Bank	386,568	$2.91M	0.0%	+6.2%	0.187%
2/10/2025	Connor Clark & Lunn Investment Management Ltd.	633,864	$4.77M	0.0%	-7.1%	0.306%
2/10/2025	Jupiter Asset Management Ltd.	1,177,929	$8.86M	0.1%	+10.1%	0.569%
2/7/2025	HighTower Advisors LLC	17,600	$0.13M	0.0%	-7.7%	0.008%

Data available starting January 2016

See Full Table

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $8.61

$8.41

$8.66

50 Day Range

MA: $8.11

$7.06

$9.39

52 Week Range

Now: $8.61

$4.03

$9.50

Volume

4,230,228 shs

Average Volume

3,090,208 shs

Market Capitalization

$1.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Who are the company insiders with the largest holdings of BioCryst Pharmaceuticals?: BioCryst Pharmaceuticals' top insider shareholders include:
Helen M Thackray (Insider)
Anthony Doyle (CFO)
Nancy J Hutson (Director)
Steven K Galson (Director)
Alan G Levin (Director)
Amy E Mckee (Director)
Machelle Sanders (Director)
Steve Aselage (Director)
Learn More about top insider investors at BioCryst Pharmaceuticals.
Who are the major institutional investors of BioCryst Pharmaceuticals?: BioCryst Pharmaceuticals' top institutional shareholders include:
Vanguard Group Inc. — 10.57%
Deerfield Management Company L.P. Series C — 3.93%
Geode Capital Management LLC — 2.33%
Nuveen Asset Management LLC — 1.65%
Fisher Asset Management LLC — 1.54%
Caligan Partners LP — 1.45%
Learn More about top institutional investors of BioCryst Pharmaceuticals stock.
Which major investors are selling BioCryst Pharmaceuticals stock?: During the last quarter, BCRX stock was sold by these institutional investors:
Price T Rowe Associates Inc. MD
Nuveen Asset Management LLC
Rock Springs Capital Management LP
Millennium Management LLC
Principal Financial Group Inc.
Trexquant Investment LP
BNP Paribas Financial Markets
Capital Fund Management S.A.
Within the previous year, company insiders that have sold BioCryst Pharmaceuticals company stock include:
Helen M Thackray (Insider)
Anthony Doyle (CFO)
Learn More investors selling BioCryst Pharmaceuticals stock.
Which major investors are buying BioCryst Pharmaceuticals stock?: Within the previous quarter, BCRX stock was bought by institutional investors including:
Vanguard Group Inc.
Eversept Partners LP
Hillsdale Investment Management Inc.
Balyasny Asset Management L.P.
Norges Bank
Woodline Partners LP
Schroder Investment Management Group
Caligan Partners LP
In the previous year, these company insiders have bought BioCryst Pharmaceuticals stock:
Helen M Thackray (Insider)
Anthony Doyle (CFO)
Nancy J Hutson (Director)
Steven K Galson (Director)
Alan G Levin (Director)
Amy E Mckee (Director)
Learn More investors buying BioCryst Pharmaceuticals stock.